PBAC's latest decision on Methylnaltrexone bromide: Recommended with restriction (2009). Considered for treatment of opioid-induced constipation in palliative care patients who have failed to respond to, or are unable to tolerate, laxative therapies.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$75k/QALY
$45k/QALY–$75k/QALY · across 2 submissions
Submissions
2
first 2009
Submissions
2
2009 → 2009
Eligible population
palliative care patients with opioid-induced constipation who have failed to respond to, or are unable to tolerate, laxative therapies
Therapy area
Pain
Line of therapy
Later-line
Evidence base
RCT
Comparator
placebo
Economic model
CUA
ICER note
Two ICER ranges presented: $15,000–$45,000 (original utility study) and $45,000–$75,000 (Van den Haak utility weights). PBAC considered true ICER likely between these ranges. Primary reliance on $45,000–$75,000 range.
ICER basis
Range aggregates 2 submissions (2009) — not a single base case.
Submission history
Mar 2009: Not recommended · Authority Required — ICER $45k/QALY